Corbus Pharmaceuticals Hldgs Inc (CRBP)

Jan 6, 2025, 8:00 AM EST - 11 days ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 7:00 AM EST - 5 weeks ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Dec 3, 2024, 7:00 AM EST - 6 weeks ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Nov 11, 2024, 4:12 AM EST - 2 months ago

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Oct 29, 2024, 8:00 AM EDT - 2 months ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 16, 2024, 8:00 AM EDT - 3 months ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Sep 26, 2024, 8:00 AM EDT - 4 months ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Sep 23, 2024, 2:01 PM EDT - 4 months ago

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Aug 26, 2024, 12:00 PM EDT - 5 months ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN GPCR SRRK VKTX

Aug 20, 2024, 8:00 AM EDT - 5 months ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Aug 6, 2024, 8:00 AM EDT - 5 months ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Jul 30, 2024, 8:50 AM EDT - 6 months ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jun 3, 2024, 1:03 PM EDT - 8 months ago

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Jun 1, 2024, 10:00 AM EDT - 8 months ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

May 30, 2024, 8:00 AM EDT - 8 months ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 8 months ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 9, 2024, 8:00 AM EDT - 9 months ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 7, 2024, 8:00 AM EDT - 9 months ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:00 AM EDT - 9 months ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Apr 24, 2024, 4:05 PM EDT - 9 months ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Apr 2, 2024, 8:00 AM EDT - 10 months ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Mar 12, 2024, 8:00 AM EDT - 11 months ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 8:00 AM EST - 11 months ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Feb 28, 2024, 8:00 AM EST - 11 months ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Feb 6, 2024, 9:50 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 2, 2024, 4:01 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 31, 2024, 9:19 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Jan 30, 2024, 6:55 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Jan 30, 2024, 7:13 AM EST - 1 year ago

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 29, 2024, 2:17 PM EST - 1 year ago

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Jan 29, 2024, 7:18 AM EST - 1 year ago

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

Jan 26, 2024, 7:30 AM EST - 1 year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Jan 23, 2024, 8:00 AM EST - 1 year ago

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Jan 9, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Dec 18, 2023, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

Nov 7, 2023, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Oct 17, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

Oct 3, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert' Series (Session 2) on CRB-701 on October 10, 2023

Sep 27, 2023, 9:05 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 8, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 31, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

Jun 26, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Set to Join Russell Microcap® Index

May 31, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 1, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting

Apr 18, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old Target

Apr 17, 2023, 8:30 AM EDT - 1 year ago

Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting